__NUXT_JSONP__("/drugs/Azercabtagene_Zapreleucel", (function(a,b,c,d){return {data:[{drug:{slug:b,emaEpar:[],fdaDrugLabel:[],id:b,nciThesaurus:{casRegistry:a,chebiId:a,chemicalFormula:a,definition:"A preparation of allogeneic, off-the-shelf, T-lymphocytes that have been genetically modified using a proprietary synthetic nuclease-based system to express a chimeric antigen receptor (CAR) targeting the tumor-associated antigen (TAA) CD19 (cluster of differentiation 19) with potential immunostimulating and antineoplastic activities. Upon administration, azercabtagene zapreleucel specifically recognize and kill CD19-expressing tumor cells. CD19 antigen is a B-cell specific cell surface antigen, which is expressed in all B-cell lineage malignancies and normal B-cells.",fdaUniiCode:"PFZ3AP93TA",identifier:"C158558",preferredName:c,semanticType:"Cell",subclassOf:["C129826","C176018","C28676"],synonyms:["AZERCABTAGENE ZAPRELEUCEL","Allogeneic Anti-CD19-CAR T-cells PBCAR0191","Allogeneic Anti-CD19-CAR T-lymphocytes PBCAR0191","Anti-CD19-CAR Allogeneic T-cells PBCAR0191",c,"PBCAR0191"]},dir:"\u002Fdrugs",path:"\u002Fdrugs\u002FAzercabtagene_Zapreleucel",extension:".json",createdAt:d,updatedAt:d}}],fetch:{},mutations:void 0}}("","Azercabtagene_Zapreleucel","Azercabtagene Zapreleucel","2021-10-30T13:34:49.733Z")));